Press Releases

 
Press Releases
  Date Title View
Feb 23, 2017
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® E...
Feb 9, 2017
2016 royalties earned up 119% vs. 2015 Royalties earned in Q4 2016 of $46.8 million, up 80% from Q4 2015 Net income for Q4 2016 of $25.5 million, or $0.24 per share, and adjusted earnings per share of $0.26 per share Announced a new $150 million ...
Feb 2, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and full year ended December 31, 2016 after market close on Thursday, February 9, 2017. Following the earnings release, Innoviva management will host a webcast and confere...
Dec 19, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) when compared to ther...
Dec 2, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/...
Dec 2, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various symptom...
Nov 21, 2016
BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol ...
Oct 31, 2016
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will be presenting at two conferences in November 2016. The details are as follows: CreditSuisse 25th Annual Healthcare ConferenceMon...
Oct 27, 2016
Q3 2016 royalty revenue earned up 118% vs Q3 2015 Net income of $15.0 million, or $0.14 per share, and adjusted earnings per share of $0.17 per share Appointed Patrick G. LePore as a director of Innoviva Management will host a conference call and...
Oct 19, 2016
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2016 after market close on Thursday, October 27, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss ...
FirstPrevious
3
...
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$13.68 0.49 (3.72%) 07/27/17 4:00 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.